A new treatment method for Alzheimer's Disease
A novel therapeutic approach for Alzheimer Disease (AD)
['FUNDING_R21'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-10740016
This study is exploring a new way to help people with Alzheimer's by boosting a important substance in the body called NAD+, which might improve brain function and slow down memory loss, using a special method that involves your own blood cells.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-10740016 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating Alzheimer's Disease by focusing on increasing levels of a crucial metabolite called NAD+ in the body. The study aims to use genetic interventions to enhance the production of NAD+ in red blood cells, which could help improve brain function and slow the progression of Alzheimer's. By using a specific type of virus to deliver genetic material to the patient's own blood stem cells, the researchers hope to create a sustained increase in NAD+ levels throughout the body. This innovative method could potentially provide a new way to combat the cognitive decline associated with Alzheimer's Disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's Disease who may benefit from enhanced metabolic function in the brain.
Not a fit: Patients with advanced Alzheimer's Disease or those who do not have a diagnosis of Alzheimer's may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that slows down or improves cognitive decline in Alzheimer's patients.
How similar studies have performed: While the approach of using genetic interventions for NAD+ elevation is innovative, similar strategies targeting metabolic dysfunction in neurological disorders have shown promise in preliminary studies.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DING, SHINGHUA — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: DING, SHINGHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.